Effectiveness of bupropion sustained release for smoking cessation in a health care setting - A randomized trial

被引:115
作者
Swan, GE
McAfee, T
Curry, SJ
Jack, LM
Javitz, H
Dacey, S
Bergman, K
机构
[1] SRI Int, Ctr Hlth Sci, Menlo Pk, CA 94025 USA
[2] Grp Hlth Cooperat Puget Sound, Ctr Hlth Promot, Seattle, WA 98121 USA
[3] Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, Seattle, WA 98101 USA
[4] Grp Hlth Cooperat Puget Sound, Ctr Pharm Adm, Seattle, WA 98101 USA
关键词
D O I
10.1001/archinte.163.19.2337
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The efficacy of bupropion hydrochloride sustained release (SR) (Zyban) for smoking cessation has been evaluated in clinical trials that included frequent in-person behavioral counseling, but not in actual practice settings. Objective: To determine the differential effectiveness of 2 doses of bupropion SR in combination with behavioral interventions of minimal to moderate intensity in an actual practice setting. Design: Open-label randomized trial, with 1 year of follow-up. Setting: A large health system (Group Health Cooperative) based in Seattle. Participants: Adult smokers (N=1524) interested in quitting smoking. Interventions: Participants were randomly assigned to receive 1 of 4 combinations of bupropion SR (150 or 300 mg) and behavioral counseling (minimal or moderate intensity). Main Outcome Measures: The primary outcome measure was self-reported point-prevalence 7-day nonsmoking status at 3 and 12 months following the target quit date. Secondary outcomes included adverse and abstinence effects reported since beginning treatment with bupropion SR. Results: At 3 months, a significantly higher rate of nonsmoking was observed among those receiving the larger bupropion SR dose (P=.005). At 12 months, moderate intensity counseling was associated significantly with a higher rate of nonsmoking (P=.001). At 3 months, the higher dose was associated with a significantly increased frequency of self-reported symptoms such as difficulty sleeping (P=.02), difficulty concentrating (P=.02), shakiness/tremor (P=.002), and gastrointestinal problems (P=.005)and a decreased frequency of reported desire to smoke (P=.001). Conclusions: In this actual practice setting, the combination of bupropion SR and minimal or moderate counseling was associated with 1-year quit rates of 23.6% to 33.2%. This suggests that existing health care systems can substantially decrease tobacco use rates among their enrollees if they provide these modest interventions.
引用
收藏
页码:2337 / 2344
页数:8
相关论文
共 26 条
[21]   COST-EFFECTIVENESS COMPARISONS USING REAL-WORLD RANDOMIZED TRIALS - THE CASE OF NEW ANTIDEPRESSANT DRUGS [J].
SIMON, G ;
WAGNER, E ;
VONKORFF, M .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 1995, 48 (03) :363-373
[22]   Aids to quitting tobacco use: How important are they outside controlled trials? [J].
Solberg, LI ;
Boyle, RG ;
Davidson, G ;
Magnan, S ;
Carlson, CL ;
Alesci, NL .
PREVENTIVE MEDICINE, 2001, 33 (01) :53-58
[23]  
SRNT Subcommittee on Biochemical Verification, 2002, Nicotine Tob Res, V4, P149, DOI 10.1080/14622200210123581
[24]   Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial [J].
Tashkin, DP ;
Kanner, R ;
Bailey, W ;
Buist, S ;
Anderson, P ;
Nides, MA ;
Gonzales, D ;
Dozier, G ;
Patel, MK ;
Jamerson, BD .
LANCET, 2001, 357 (9268) :1571-1575
[25]   ASSESSING OUTCOME IN SMOKING CESSATION STUDIES [J].
VELICER, WF ;
PROCHASKA, JO ;
ROSSI, JS ;
SNOW, MG .
PSYCHOLOGICAL BULLETIN, 1992, 111 (01) :23-41
[26]   Measuring adherence to behavioral and medical interventions [J].
Vitolins, MZ ;
Rand, CS ;
Rapp, SR ;
Ribisl, PM ;
Sevick, MA .
CONTROLLED CLINICAL TRIALS, 2000, 21 (05) :188S-194S